Baxter International Inc.BAXNYSE
Loading
A large-scale business currently unprofitable
Baxter International Inc. , through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit.
Comprehensive financial statement data for deep analysis
| Metric | Dec 21 | Dec 22 | Dec 23 | Dec 24 | Dec 25 |
|---|---|---|---|---|---|
| Return on Equity | - | - | - | - | - |
| Return on Invested Capital | - | - | - | - | - |
| Gross Margin | 40.8% | 38.1%↓6.7% | 38.5%↑1.0% | 36.2%↓5.8% | 33.0%↓9.0% |
| Operating Margin | 16.3% | 11.3%↓30.6% | 8.7%↓22.9% | 6.5%↓25.9% | 6.2%↓4.6% |
| Net Margin | 10.0% | -16.8%↓267.0% | -2.2%↑87.0% | -6.1%↓179.7% | -9.4%↓53.6% |
| Earnings Yield | - | - | - | - | - |